Preston Klassen

Preston S.
Klassen formerly worked at Metacrine, Inc., as President, Chief Executive Officer & Director from 2020 to 2023, Amgen, Inc., as Executive Director-Medical from 2002 to 2009, Conatus Pharmaceuticals, Inc., as Independent Director from 2014 to 2020, Regulus Therapeutics, Inc., as President, Director & Head-Research & Development from 2023 to 2025, Corvidia Therapeutics, Inc., as Director, Equillium, Inc., as Director, Chinook Therapeutics, Inc., as Director, Arena Pharmaceuticals, Inc., as Chief Medical Officer, Executive VP, Head-R&D from 2017 to 2020, Orexigen Therapeutics, Inc., as Executive VP & Head-Global Development from 2009 to 2016, Sanifit Therapeutics SA, as President & Chief Medical Officer from 2016 to 2017, Sanifit, Inc., as President & Chief Marketing Officer, and Zura Bio Ltd., as President & Chief Operating Officer in 2023.
Dr. Klassen received his graduate degree in 2000 from Duke University, undergraduate degree from Central College, and doctorate degree from the University of Nebraska Medical Center.